Figure 2.
Peto odds ratio (OR) of major adverse cardiovascular events in patients treated with (a) biologic therapies vs. placebo; (b) tumour necrosis factor‐α inhibitors (TNFi) vs. placebo, (c) anti‐interleukin‐(IL)‐17A agents vs. placebo; and (d) ustekinumab vs. placebo. CI, confidence interval; df, degrees of freedom.